Back to search results
NCT06618157

Connectomic Guided DBS for Parkinson's Disease

Enrolling by Invitation
NAAges 18+InterventionalTreatment
Duke University
~20 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:Cerebellothalamic optimized deep brain stimulationPallidothalamic optimized deep brain stimulationNo deep brain stimulationUsual care deep brain stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tremor duration as measured by wearables
Measured over Approximately eight hours
+3 more outcomes measured

Conditions

Parkinson Disease
Tremor
Dyskinesias

Explore related trials

Parkinson Disease

NCT06618157

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Duke Health Center at Morreene Road

    Durham, North Carolinano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kyle Mitchell, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 or older
Diagnosed with Parkinson's disease and has previously been implanted with bilateral subthalamic nucleus deep brain stimulation (DBS)
Received DBS at least three months prior to the time of the study to allow for optimization of usual clinical care
With at least mild tremor on a pre-operatory MDS-UPDRS clinical scale as defined by at least 2 out of 4 resting tremor grading on MDS-UPDRS on at least one extremity

Exclusion

Not having a post-operative head CT with 1mm or smaller axial slices at least 1 week after initial lead implantation.
Patients who received DBS less than three months prior to the start of the study

What this trial measures

  • Tremor duration as measured by wearablesApproximately eight hours

    An Apple iPhone will be used to collect about two hours of data of each participant using accelerometer to estimate tremor duration. This technology has been integrated into the StrivePD application (Rune Labs, San Francisco, CA) and has been used in other studies at Duke University.

  • Tremor severity as measured by wearablesApproximately eight hours

    An Apple iPhone will be used to collect about two hours of data of each participant using accelerometer to estimate tremor severity. This technology has been integrated into the StrivePD application (Rune Labs, San Francisco, CA) and has been used in other studies at Duke University.

  • Dyskinesia duration as measured by wearablesApproximately eight hours

    An Apple iPhone will be used to collect about two hours of data of each participant using accelerometer to estimate dyskinesia severity duration). This technology has been integrated into the StrivePD application (Rune Labs, San Francisco, CA) and has been used in other studies at Duke University.

  • Dyskinesia severity as measured by wearablesApproximately eight hours

    An Apple iPhone will be used to collect about two hours of data of each participant using accelerometer to estimate dyskinesia severity. This technology has been integrated into the StrivePD application (Rune Labs, San Francisco, CA) and has been used in other studies at Duke University.